Biotech Values

[DewDiligence]

ENTA/ASMB—Under no pressure from the investment community to rush its HBV program (thanks to the ample royalty income from HCV and its further advanced clinical programs in NASH and RSV), ENTA has spent several years selecting its lead HBV candidate, which is the polar opposite of the approach taken by ASBM. In short, I’m pretty confident that ENTA’s HBV CpAM compound will be a good one.